Cardiac Arrhythmias in Cancer Patients

Chapter

Abstract

Patients with cancer may have several kinds of arrhythmias either as an independent comorbidity or as a consequence of the cancer itself or of the antineoplastic therapies.

References

  1. 1.
    Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37(4):300–11.CrossRefPubMedGoogle Scholar
  2. 2.
    Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34(15):1102–11.CrossRefPubMedGoogle Scholar
  3. 3.
    Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719–47.CrossRefPubMedGoogle Scholar
  4. 4.
    Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–42.CrossRefPubMedGoogle Scholar
  5. 5.
    Driver JA, Djoussé L, Logroscino G, Gaziano JM, Kurth T. Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study. BMJ. 2008;337:a2467.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    D’Amico T, Zhao Y, O’Brien S, Harpole D. Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database. Ann Thorac Surg. 2010;90:368–74.CrossRefPubMedGoogle Scholar
  7. 7.
    Siu CW, Tung HM, Chu KW, Jim MH, Lau CP, Tse HF. Prevalence and predictors of new-onset atrial fibrillation after elective surgery for colorectal cancer. Pacing ClinElectrophysiol. 2005;28 Suppl 1:S120–3.19.CrossRefGoogle Scholar
  8. 8.
    Bhave PD, Goldman LE, Vittinghoff E, Maselli J, Auerbach A. Incidence, predictors, and outcomes associated with postoperative atrial fibrillation after major non cardiac surgery. Am Heart J. 2012;164:918–24.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Guzzetti S, Costantino G, Vernocchi A, Sada S, Fundaro C. First diagnosis of colorectal or breast cancer and prevalence of atrial fibrillation. Intern Emerg Med. 2008;3:227e231.CrossRefGoogle Scholar
  10. 10.
    Velagapudi P, Turagam MK, Kocheril AG. Atrial fibrillation in cancer patients: an underrecognized condition. South Med J. 2011;104:667–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Lainscak M, Dagres N, Filippatos GS, Anker SD, Kremastinos DT. Atrial fibrillation in chronic non-cardiac disease: where do we stand? Int J Cardiol. 2008;128:311–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Lee AY. Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices. Dis Mon. 2005;51:150–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J ClinOncol. 2005;23:2130–5.CrossRefGoogle Scholar
  14. 14.
    Connolly SJ, Ezekowitz MD, Yusuf S, et al. For the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.CrossRefPubMedGoogle Scholar
  15. 15.
    Lee Y-J, Park J-k, Uhm J-S, Kim J-Y, Pak H-N, Lee M-H, Sung J-H, Joung B. Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy International. J Cardiol. 2016;203:372–8.Google Scholar
  16. 16.
    Frendl G, Sodickson AC, Chung MK, et al.; American Association for Thoracic Surgery. 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. J Thorac Cardiovasc Surg. 2014;148(3):e153–93. Epub 2014 Jun 30. Review.Google Scholar
  17. 17.
    Hinterseer M, Becker A, Kaab S, Lang N, Nabauer M, Steinbeck G. Thalidomide-induced symptomatic third-degree atrioventricular block. Clin Res Cardiol. 2006;95:474–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Fahdi IE, Gaddam V, Saucedo JF, Kishan CV, Vyas K, Deneke MG, et al. Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol. 2004;93(8):1052–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354(10):1021–30.CrossRefPubMedGoogle Scholar
  20. 20.
    Ettinger DS, Armstrong DK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989;111(4):273–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Arbuck SG, Strauss H, Rowinsky E, Christian M, Suffness M, Adams J, et al. A reassessment of cardiac toxicity associated with taxol. J Natl Cancer Inst Mono. 1993;15:117–30.Google Scholar
  22. 22.
    Yavas O, Aytemır K, Celık I. The prevalence of silent arrhythmia in patients receiving cisplatin-based chemotherapy. Turkish J Cancer. 2008;38(1):12–5.Google Scholar
  23. 23.
    Eskilsson J, Albertsson M. Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol. 1990;29(8):1001–3.CrossRefPubMedGoogle Scholar
  24. 24.
    Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res ClinOncol. 2008;134(1):75–82.CrossRefGoogle Scholar
  25. 25.
    Oleksowicz L, Escott P, Leichman GC, Spangenthal E. Sustained ventricular tachycardia and its successful prophylaxis during high-dose bolus interleukin-2 therapy for metastatic renal cell carcinoma. Am J ClinOncol. 2000;23:34–6.CrossRefGoogle Scholar
  26. 26.
    Quezado ZM, Wilson WH, Cunnion RE, Parker MM, Reda D, Bryant G, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993;118(1):31–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Cazin B, Gorin NC, Laporte JP, Gallet B, Douay L, Lopez M, et al. Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer. 1986;57(10):2061–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Kupari M, Volin L, Suokas A, Timonen T, Hekali P, Ruutu T, et al. Cardiac involvement in bone marrow transplantation:electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant. 1990;5(2):91–8.PubMedGoogle Scholar
  29. 29.
    Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6–19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol. 1995;24(6):352–61.CrossRefPubMedGoogle Scholar
  30. 30.
    Haqqani HM, Morton JB, Kalman JM. Using the 12-lead ECG to localize the origin of atrial and ventricular tachycardias: part 2--ventricular tachycardia. J Cardiovasc Electrophysiol. 2009;20(7):825–32.CrossRefPubMedGoogle Scholar
  31. 31.
    Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36:295.CrossRefPubMedGoogle Scholar
  32. 32.
    US FDA drug approval summary for vandetanib in medullary thyroid cancer. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf. Accessed 25 Apr, 2011.
  33. 33.
    Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoSOne. 2012;7, e30353.CrossRefGoogle Scholar
  34. 34.
    FDA-approved manufacturer's package insert for vandetanib. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525. Accessed 25 Jan 2013.
  35. 35.
    Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J ClinOncol. 2008;26:5204.CrossRefGoogle Scholar
  36. 36.
    Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J ClinOncol. 2007;25:3362.CrossRefGoogle Scholar
  37. 37.
    Bello CL, Mulay M, Huang X, et al. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res. 2009;15:7045.CrossRefPubMedGoogle Scholar
  38. 38.
    Tolcher AW, Appleman LJ, Shapiro GI, et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2011;67:751.CrossRefPubMedGoogle Scholar
  39. 39.
    US Food and Drug Administration (FDA)-approved manufacturer's package insert. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=807f988e-117b-4497-934d-73aa78baac71. Accessed 03 Jan 2013.

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Division of Cardiology, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’ - IRCCSNaplesItaly

Personalised recommendations